Premium-Grade Research Peptides You Can Trust!!
PT-141, also known as bremelanotide, improves sexual function in both men and women by stimulating the melanocortin receptors in the brain. This induces a heightened sense of arousal and sexual desire. PT-141 also increases blood flow to the penis or vagina and clitoris, improving intimate experiences.
As a result, users will experience increased libido and sexual desire, improved sexual function, improved female sexual arousal disorder (FSAD), and increased lubrication, orgasms, and satisfaction.
Enhanced purity standards with third-party verification and GMP certification.
Recommended Dose: Inject 5 units (500mcg) daily.
Administration: Subcutaneous injection
Timing: On an empty stomach, at least 1 hour before/after eating..
Cycle: Best results occur when taken consistently for 4-12 weeks.
99% Purity tested via HPLC methods.
Store in a cool and dry place away from children.
2 vials, all supplies included
4 vials, all supplies included
Using our dosage recommendations listed above, 1 vial will provide 40 500mcg (5 unit) doses, lasting 5.71 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vial can be used, if desired. However, only 28 doses are needed for the 4 week protocol.
Using our dosage recommendations listed above, 3 vials will provide 120 500mcg (5 unit) doses, lasting 17.14 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vials can be used, if desired. However, only 84 doses are needed for the 12 week protocol.
Published in 2019 in Obstetrics & Gynecology, these identical phase 3 RECONNECT trials (n=1,202 premenopausal women) showed that as-needed subcutaneous bremelanotide (1.75 mg) significantly increased sexual desire and reduced related distress over 24 weeks, with a favorable safety profile (main side effects: nausea, flushing), marking it as a breakthrough central-acting therapy for HSDD.
Read StudyPublished in 2019 in Obstetrics & Gynecology, this 52-week open-label extension of the RECONNECT trials (following the core phase 3 studies) demonstrated sustained improvements in desire and distress for premenopausal women with HSDD, with no new safety signals emerging; common side effects remained mild (e.g., nausea in ~40%), supporting long-term use potential.
Read StudyPublished in 2021 in the Journal of Sexual Medicine, this qualitative and quantitative analysis of exit surveys/interviews from RECONNECT participants highlighted meaningful real-world benefits, including increased sexual desire, physical arousal, and improved relationship intimacy with bremelanotide, providing patient-centered evidence of its impact beyond statistical endpoints.




Based on 0 reviews
You must be logged in to post a review.
There are no reviews yet.
Reviews